Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARMYDA-AMULET
2024-515361-34-00Phase 4Authorised
- Sponsor
- Fondazione Toscana Gabriele Monasterio
- Start
- Oct 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aspirin and clopidogrel in Atrial fibrillation (AFib) (2 arms), sponsored by Fondazione Toscana Gabriele Monasterio. Primary endpoint: Net composite endpoint at 6 months. Planned start Oct 2021; status: authorised.
02
Drugs
aspirinclopidogrel
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2024-515361-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515361-34-00.